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Abstract
The uncomfortable symptoms of atopic dermatitis (AD) often trigger psychological stress.
We investigated the association between AD severity and outpatient visits to psychiatrists using Korean National Health Insurance
claims data from 2004 to 2013.
This was a retrospective cohort analysis; we estimated hazard ratios (HRs).
Of the 266,182 subjects, 18,290 (6.9%) had a history of visiting a psychiatrist, and 25,419 (9.5%) were diagnosed with AD.
Compared with the subjects without AD, subjects with AD had a higher HR for visiting a psychiatrist (3.70, 95% conﬁdence interval
[CI]:48 3.43–3.98), and this signiﬁcantly increased as the complexity of the ADmedications increased. Subjects who received topical
treatments plus a systematic steroid (HR: 4.88, 95% CI: 4.51–5.27) and those who received topical treatments plus a systematic
steroid plus a systematic calcineurin inhibitor (HR: 9.56, 95% CI: 4.29–21.28) had higher HRs compared with those without AD.
Severe AD patients exhibited greater psychological stress than those without AD or with mild AD symptoms. Moreover, medication
diversity may represent an efﬁcient and low-cost method by which to identify a vulnerable population.
Abbreviations: AD= atopic dermatitis, BBB= blood–brain barrier, BDNF= brain-derived neurotrophic factor, CESD=Center for
Epidemiologic Studies Depression Scale, CI = conﬁdence interval, DLQI = Dermatology Life Quality Index, EASI = Eczema Area and
Severity Index, fMRI = functional magnetic resonance imaging, HR = hazard ratio, ICD = International Classiﬁcation of Diseases, IRB
= Institutional Review Board, NHI = National Health Insurance, NHICD = National Health Insurance cohort data, PET = positron
emission tomography.
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11. Introduction
Atopic dermatitis (AD) is a chronic inﬂammatory skindisorder that
causes itching.[1,2] This pruritic skin disorder typically occurs
during childhoodor earlypubertybutmaypersist throughoutone’s
lifetime with a waxing andwaning clinical course. Since the 1960s,
there has beena3-fold increase in theprevalence ofAD[3] and, thus,
this chronic inﬂammatory disorder of the skin has become a major
global public health concern. In the United States, Northern and
Western Europe, Japan, Korea, andAustralia, 10–20%of children
are thought to have AD.[4] In Korea, the prevalence of AD in
children younger than 24 months increased from 19.8% to 23.8%
between 2003 and 2008,[5] and its incidence in the general Korean
general population aged 19 years and older is 7.1%.[6]
Because AD is usually accompanied by annoying itching and
discomfort during routine everyday life, it is an emerging social
concern in many developed countries.[7] Furthermore, these types
of uncomfortable symptoms are often associated with psycho-
logical stress and impaired achievement at school.[8] Therefore, it
is important to assess the levels of psychological stress in AD
patients and to develop methods to prevent psychological and
physical problems. However, it is difﬁcult to measure the
increased risk of psychological burden among AD patients using
population-based approaches. Thus, the present study attempted
to investigate the relationship between increased severity of AD
and psychological stress and burden using national claims data
for 2002 to 2013. Additionally, this study sought to identify the
age groups and speciﬁc types of psychological disorder that are
especially likely to be associated with a history of AD.
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2.1. Data
We analyzed the Korea National Health Insurance Cohort Data
(NHICD), which includes information about ∼1 million patients.
This information was obtained from a random sample that was
stratiﬁed according to age, sex, region, health insurance type,
income decile, and individual total medical costs in 2002; the
participants were reassessed and followed until 2013. The
NHICD includes unique anonymous numbers for each patient as
well as their age, sex, type of insurance, diagnoses according to
the International Classiﬁcation of Diseases (ICD-10), medical
costs claimed, prescription drugs, andmedical history.Moreover,
these unique anonymous numbers are linked to mortality
information, which was obtained from the Korean National
Statistical Ofﬁce. The Institutional Review Board (IRB) of the
Graduate School of Public Health at Yonsei University approved
use of these data as well as the study design (IRB approval
number: 2-1040939-AB-N-01-2014-239).2.2. Participants
On December 31, 2002, a total of 1,025,340 NHICD
participants were selected for the present study. From this initial
population, a cohort of subjects younger than 20 years of age
who had been newly diagnosed with AD (ICD-10 code: L20) was
chosen for the present analyses based on their natural history of
AD. To improve the accuracy of the AD diagnosis, the main
diagnosis of each patient, but not any concurrent comorbidity
observed during their outpatient visits to medical specialists,
including dermatologists and pediatricians, was assessed. In total,
111,688 patients with a history of skin symptoms who had been
diagnosed with AD bymedical specialists during the examination
period were selected from the initial population. Because the
present study aimed to assess only new cases of AD, the data of
77,867 subjects with a history of AD from 2002 to 2004 were not
included in the present analyses. Furthermore, 8402 subjects whoStratified Random 
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Figure 1. Flowchart showing sample selection. This is a stratiﬁed random sampled
population aged 20 or under 378,875 patients. Then we divided the AD patients an
the previous AD history before 2005 (n=77,867) or psychiatric diagnosis (n=2
participants, we only excluded the subjects with psychiatric diseases before 2005
AD = atopic dermatitis.
2had already been diagnosed with a psychiatric disorder prior to
the diagnosis of AD were excluded. The present study also
included 244,462 carefully selected control subjects aged 20 years
of age or younger. Thus, this study included a total of 266,182
subjects, 25,429 of whom were AD patients and 240,763 of
whom were control subjects (Fig. 1).
2.3. Covariates
We assessed a number of demographic characteristics, including
age, sex, and area of residence. Socioeconomic characteristics,
such as the income level and the type of medical insurance, were
also assessed, and the NHI premiumwas used as a proxymeasure
of precise income because it is proportional to monthly income,
including earnings and capital gains. The income deciles of the
NHI members were categorized into the following 4 groups: low,
(ﬁrst and second deciles), low–middle (third to ﬁfth deciles),
high–middle (sixth to eighth deciles), and high (ninth to tenth
deciles).2.4. Severity of AD
The severity of AD was measured by reference to the complexity
of medications prescribed to treat AD symptoms. Many AD
patients with very mild symptoms experience improvements
without any medical treatment by using moisturizers and
avoiding speciﬁc allergens.[9–11] For patients with more severe
AD, doctors may prescribe topical or oral medications according
to the treatment guidelines for AD.[1,12]
Accordingly, all AD patients were categorized based on these
operational criteria into the following groups: AD without
treatment, AD with topical treatment only, AD with topical
treatment plus a systematic steroid, and AD with topical
treatment plus a systematic steroid plus a systematic calcineurin
inhibitor.
Topical treatment referred to the topical use of any
corticosteroid or calcineurin inhibitor, whereas systematicSample of 
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cohort study with approximately a million subjects. First, we only selected the
d non-AD control for all the participants. In terms of AD patients, if someone has
5,419), then we excluded such subject. Similarly, among the initial control
(n=3701). After that, we designed to start the observation from 2005 January.
Table 1
Demographic characteristics of control subjects and patients with atopic dermatitis.
Demographic characteristic
Atopic dermatitis
Control subjects Patients Total
PN % N % N
Gender
Male 128,262 53.3 13,118 51.6 141,380 <0.001
Female 112,501 46.7 12,301 48.4 124,802
Age during enrollment
0 45,148 18.8 17,983 70.7 63,131 <0.001
1–5 23,655 9.8 2775 10.9 26,430
6–10 51,776 21.5 2088 8.2 53,864
10–14 58,913 24.5 1317 5.2 60,230
15–20 61,271 25.4 1256 4.9 62,527
Residential area
Rural 76,623 31.8 7365 29.0 83,988 <0.001
Urban 164,140 68.2 18,054 71.0 182,194
Type of insurance
Employee 112,156 46.6 8838 34.8 120,994 <0.001
Self-employed 120,046 49.9 16,281 64.1 136,327
Medical aid 8561 3.6 300 1.2 8861
Income level
Lowest 28,540 11.9 2036 8.0 30,576 <0.001
Low-middle 53,705 22.3 6058 23.8 59,763
Middle-high 91,812 38.1 11,616 45.7 103,428
Highest 66,706 27.7 5709 22.5 72,415
Psychiatric disorders <0.001
No 225,729 93.8 22,163 87.2 247,892
Yes 15,034 6.2 3256 12.8 18,290
Rate of psychiatric disorders (cases/100,000 person-years)
Rate, 95% CI 812.2 (799.3–825.3) 2,862.5 (2765.9–2962.5) 930.9 <0.001
Total, N, % 240,763 90.5 25,419 9.5 266,182
Baseline categorical variables were expressed as numbers and percentages and compared with a chi-square (x2) test.
Rates of psychiatric disorders were compared using Student’s t-tests.
Shin et al. Medicine (2016) 95:49 www.md-journal.comtreatment was deﬁned as oral, intramuscular, or intravenous
administration of a corticosteroid.2.5. Outcome measures
The primary outcome measure was deﬁned as an outpatient visit
to a psychiatric specialist. Although a number of other quality-
adjusted outcomes for measuring the mental health of AD
patients, such as the Center for Epidemiologic Studies Depression
Scale (CESD)-11 or the Dermatology Life Quality Index (DLQI),
may be available for hospital-based research, the use of
population-based claims data in the present study made it
impossible to use such measurements. Additionally, subjects with
a history of medical visits for any psychiatric disorder prior to AD
onset or the initial follow-up period were excluded from the
present analyses.2.6. Statistical analysis
We assessed the demographic characteristics of AD patients at
baseline. Continuous variables were expressed as means,
standard deviations (SDs), or medians and were compared using
Student’s t-tests or Kruskal–Wallis tests, as appropriate. Baseline
categorical variables were expressed as numbers and percentages
and compared with a chi-square (x2) test. Additionally, the
adjusted hazard ratios (HRs) and 95% conﬁdence intervals (CIs)
for visits to a psychiatrist were estimated by applying a Cox
proportional-hazard regression model. Model ﬁtting was3performed using the PHREG command in SAS version 9.3
(SAS Institute Inc.; Cary, NC).3. Results
3.1. General characteristics of study subjects
The present study included 266,182 subjects from the target
population, and 1,964,831 person-years were examined during
the study period (Table 1). Of these subjects, 25,419 were AD
patients (9.5%), and 18,290 (6.9%) had a history of visiting a
psychiatrist at least once during the follow-up period. AD
patients were twice as likely to have visited a psychiatrist as non-
AD subjects (x2, P<0.001). A comparison of the rates of
psychiatric disorders between the groups (psychiatric disorder
cases per 100,000 person-years) revealed that the AD patients
were 3 times more likely than the control subjects to have a
psychiatric disorder (P<0.001).
Of the AD patients, 41.4% had used only a topical medication,
37.9% did not use a speciﬁc medication, and 17.4% had a history
of systemic steroidal use (Table 2). An analysis of the history of
psychiatric visits revealed that the total AD patient group (all
treatments, including those prescribed a systematic calcineurin
inhibitor) was 3 times more likely to have experienced psychologi-
cal problems than was the AD group who had not received
treatment (P<0.001). AnunadjustedKaplan–Meier analysis using
the log-rank test also revealed that AD patients had a signiﬁcantly
greater chance of visiting a psychiatrist (P<0.001; Fig. 2).
Table 2
Severity of atopic dermatitis and outpatient visits to psychiatrists.
Severity of AD
Visits to psychiatrist
No Yes Total
N % N % N P
Treatment categories
No treatment 8533 38.5 1087 33.4 9620 <0.001
Topical treatment 9250 41.7 1277 39.2 10,527
Topical + systematic steroid 3614 16.3 784 24.1 4398
Topical + systematic steroid + systematic calcineurin inhibitors 14 0.1 8 0.2 22
Other treatments 752 3.4 100 3.1 852
Total 22,163 100.0 3256 100.0 25,419
Systematic administration means any medication via oral, intramuscular, and intravenous routes.
Chi-square test was performed for calculating P.
AD = atopic dermatitis.
Shin et al. Medicine (2016) 95:49 Medicine3.2. Multivariate analysis of the HR for visiting
a psychiatrist
Patients with AD had a signiﬁcantly increased adjusted HR
(adjusted HR: 3.29, 95% CI: 3.16–3.42) for psychiatric visits for
all psychiatric disorders (including affective, anxiety, and
pediatric disorders) compared with the controls (Fig. 3). In
particular, the likelihood of visiting a psychiatrist for a pediatric
psychiatric disorder was ∼5 to 6 times higher for AD patients
compared with those without AD (adjusted HR: 5.76, 95% CI:
5.40–6.15).
Compared with subjects without a history of AD, patients with
a medical history of AD only, and who were not speciﬁcally
treated, had a higher adjusted HR for psychiatric visits (adjusted
HR: 3.70, 95% CI: 3.43–3.98; Table 3). Additionally, the
adjusted HRs signiﬁcantly increased with the complexity of the
AD medication regimen. AD patients who had received only a
topical treatment showed had an increased HR for psychiatric
visits (adjusted HR: 4.50, 95% CI: 4.21–4.80). Moreover, AD
patients who had received a topical treatment plus a systematic
steroid (adjusted HR: 4.88, 95%CI: 4.51–5.27) and AD patients
who had received a topical treatment plus a systematic steroid
plus a systematic calcineurin inhibitor (adjusted HR: 9.56, 95%Figure 2. Cumulative incidence of outpatient visits to psychiatrists according
to the duration of atopic dermatitis.
4CI: 4.29–21.28) were associatedwith even greater increases in the
HRs for psychiatric visits.
Subgroup analysis based on age showed that young AD
patients, especially those aged 6 to 10 years, had increased
adjusted HRs for visiting a psychiatric clinic (Supplementary
Figure 1, http://links.lww.com/MD/B428) as the variety of their
medications increased. In addition, AD patients in both areas
showed a gradually increasing tendency toward a higher HR as
the complexity of their medication regimen increased (Supple-
mentary Figure 2, http://links.lww.com/MD/B428).4. Discussion
Several studies have investigated the relationship between AD
and psychiatric disorders, particularly depressive mood
disorders.[7,13–15] Similar to these studies, the present investigation
using a large sample size and a longitudinal design supported the
hypothesis that there is a positive association between AD and an
increased risk of affective, anxiety, and/or pediatric psychiatric
disorders.Additionally, this studyalso evaluated the severityofAD
and found a dose-dependent relationship between the severity of
this disease and the likelihood of developing a psychiatric disorder.
Basedon themost recentADtreatmentguidelines fromEurope and
North America,[12,16] it is reasonable to classify the severity of AD
according to the complexity of the medication regimen because
topical and systematic calcineurin inhibitors are both regarded as
standard treatments for this disorder.
Although the exact mechanisms underlying this relationship
require further investigation, there are several possible factors
that may link AD with the development of psychiatric disorders
or other mental health burdens.
First, many AD patients complain of sleep disturbance
associated with aggravated symptoms and have signiﬁcantly
reduced sleep efﬁciency, longer sleep-onset latency, a greater
degree of sleep fragmentation, and less nonrapid eye movement
sleep.[13,15,17–19] More speciﬁcally, higher total and/or allergen-
speciﬁc immunoglobulin E (IgE) levels are associated with lower
nocturnal melatonin secretion, which can disturb sleep induction
and maintenance.[17] Additionally, brain-derived neurotrophic
factor (BDNF) and Substance P are related to disease severity,
quality of life, and nocturnal scratching in AD patients.[20] These
types of stress-induced biological factors can interfere with the
skin barrier system, including the epidermis, and aggravate
nocturnal pruritus.[21] Thus, psychological stress and AD
symptoms appear to form a vicious circle because the sleep
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Figure 3. Adjusted HRs for outpatient visits to psychiatrists by patients with atopic dermatitis. We adjusted for gender, age group, residential area, type of
insurance, and income level. We determined HRs by subgroup. CI=conﬁdence interval, HRs=hazard ratios.
Shin et al. Medicine (2016) 95:49 www.md-journal.comdisturbances experienced by AD patients result in inappropriate
sleep quality and quantity and increase mental health problems,
including psychiatric disorders.[14,22–24]Table 3
Adjusted hazard ratios for outpatient visits to psychiatrists (all
psychiatric disorders).
HR 95% CI 95% CI P
Gender
Male 1.01 0.98 1.04 0.681
Female 1.00
Age, y
0 0.60 0.57 0.64 <0.0001
1–5 0.86 0.82 0.91 <0.0001
6–10 0.93 0.89 0.97 0.001
11–15 0.99 0.95 1.03 0.471
16–20 1.00
Residential area
Rural 1.00
Urban 1.18 1.14 1.21 <0.0001
Type of insurance
Employee 1.00
Self-employed 1.00 0.97 1.03 0.727
Medical aid 1.34 1.21 1.47 <0.0001
Income level
Lowest 0.99 0.93 1.05 0.716
Low-middle 0.96 0.92 1.00 0.039
Middle-high 0.91 0.88 0.95 <0.0001
Highest 1.00
Atopic dermatitis, AD
No AD 1.00
AD without treatment 3.70 3.43 3.98 <0.0001
AD with topical treatment 4.50 4.21 4.80 <0.0001
AD with topical + systematic steroid 4.88 4.51 5.27 <0.0001
AD with topical + systematic
steroid + systematic
calcineurin inhibitors
9.56 4.29 21.28 <0.0001
AD with other treatments 3.45 2.77 4.29 <0.0001
Systematic administration refers to oral, intramuscular, and intravenous routes.
AD = atopic dermatitis.
5Second, the negative cosmetic aspects of AD affect self-esteem
and impair interpersonal relationships. Patients with moderate-
to-severe AD typically suffer from oozing and erythematous skin
patches with scales during the acute stage of the disease.[3,18]
Moreover, the skin lesions are transformed during the transition
from the acute to the chronic phase, and the licheniﬁcation and
dark-reddish skin colors may result in signiﬁcant levels of stress in
patients’ social lives.[25] Thus, AD is associated with high levels of
stigmatization, social withdrawal, anxiety, and depression
among patients and may affect their careers.[13,15,26] AD-related
perceptions of stigma are of greater importance than more
general psychological factors when predicting AD-related quality
of life, such as the experience of depression.[27,28] Moreover,
children and adolescents with AD repeatedly experience feelings
of social isolation, peer-group rejection, teasing, and bullying,
which may lead to a loss of conﬁdence, mood changes, and/or
depression.[29,30] This is important, because these kinds of
emotional experiences can impair concentration during class; in
fact, students with severe AD are often absent from school.[31,32]
Such factors ultimately have a negative effect on education and
can lead to children becoming withdrawn[33]; it may also increase
the likelihood that they will exhibit difﬁcult behavior or even lead
to the development of pediatric and adolescent psychiatric
disorders.[7,13,26] Thus, the cosmetic discomfort of AD is
signiﬁcantly related to mental health.
Third, AD and psychiatric disorders may share pathogenic
factors related to genetic susceptibility and inﬂammation. In
terms of immunological pathways, several studies have shown
that pro-inﬂammatory cytokines secreted by eczematous inﬂam-
mation and some stress hormones, including oxytocin glucocor-
ticoid from epidermal keratinocytes, penetrate the blood–brain
barrier (BBB) and activate neuropathogenic mechanisms related
to emotional control.[34–38] In this context, it is possible that there
is an initial sequential activation of AD via the actions of
inﬂammatory cytokines and hormones and that a psychiatric
disorder may develop later. However, because there is contro-
versy regarding the bidirectional relationship between psycho-
logical factors and AD onset,[39] further investigation is needed to
elucidate the precise mechanisms underlying AD and mental
Shin et al. Medicine (2016) 95:49 Medicineillness. The present study has several limitations that should be
addressed.
First, the NHICD does not include detailed medical informa-
tion such as disease severity, personal lifestyle, perceived stress, or
other environmental factors. However, this study attempted
to adjust for all available socioeconomic factors, including
household income, insurance type, and residential area, as well as
for demographic factors, such as age, gender, and duration of
study participation.
Second, the database is not linked to family members to protect
personal privacy; thus, it was impossible to determine or adjust
for family history of allergic diseases, which is one of the most
important factors in the severity of AD. On the other hand,
because the complexity of prescribed medications was utilized
as a proxy indicator for disease severity, we at least partially
accounted for this limitation.
Third, the incidence of AD may have been overestimated,
whereas the rates of psychiatric disorders may have been
underestimated. Although only AD patients diagnosed by
board-certiﬁed dermatologists and pediatricians were included
in the present study based on the hypothesis that specialists are
able to correctly diagnose AD, it is sometimes difﬁcult to
distinguish AD from other eczematous disorders. However, as
the prevalence of AD in the study population was 9.5%, this may
reﬂect the epidemiologic characteristics of AD.
Fourth, the psychiatric visits do not mean the psychiatric
problems. Some patients might visit the clinics to consult their
insomnia without regular medication. However, we could
not distinguish this kind of patients from participants. To ﬁgure
out, we need some further investigation with health record
review.
Fifth, the other AD treatments were not considered in this
study. It is excluded that some other systematic treatments
including azathioprine, mycophenolate, and methotrexate and
phototherapy for AD. Because some of these treatments were not
covered by NHI, we could not exactly consider them.
Finally, although this study included broad CIs in the statistical
analyses, the relatively small sample size of 25,419 AD patients
may limit the generalizability of the results. Further, clinical
studies that involve matching with real medical records are
required to validate the present ﬁndings.5. Conclusions
In conclusion, this population-based longitudinal cohort study
demonstrated that child and adolescent ADpatients have a higher
risk of developing psychiatric disorders, and this risk increases as
the complexity of their medication regimen increases. Moreover,
screening for early stress and psychiatric disorders based on the
diversity of AD medications may be the easiest and most
efﬁcacious method with which to identify at-risk populations
while accruing the lowest administrative cost. However, since we
could not adjust psychological stress, the further study should be
needed for the association between AD onset and developing
psychiatric disorders.Acknowledgments
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